Dietary Fiber Supplement for Inflammation and Symptoms in COPD
Tests a dietary fiber supplement against placebo in adults with COPD.
Plain-language title generated from the registry record
Registry title: Effect of Dietary Fiber Supplementation on Systemic Inflammation and Clinical Parameters in COPD
Key facts
- Where
- Belo Horizonte, BrazilSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07868211, who can take part
Where in Brazil
- Hospital das Clínicas da UFMG - Ambulatório de Doenças Pulmonares IntersticiaisBelo Horizonte, BrazilNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Júnea Regina Pires Drews
- Trial code
- NCT07868211
- Record updated
- 14 October 2026
- Original description
Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent respiratory symptoms and systemic inflammation. Dietary fiber intake has been associated with beneficial effects on gut microbiota composition and systemic inflammatory markers. This study aims to evaluate the effects of dietary fiber supplementation on systemic inflammation and clinical parameters in patients with COPD through a randomized, double-blind, placebo-controlled trial.Read full original descriptionShow less
Efeito Da Suplementação Dietética De Fibras Sobre Inflamação Sistêmica E Parâmetros Clínicos Na DPOC: Ensaio Clínico Randomizado, Duplo-Cego E Controlado Por Placebo
Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent respiratory symptoms and systemic inflammation. Dietary fiber intake has been associated with beneficial effects on gut microbiota composition and systemic inflammatory markers. This study aims to evaluate the effects of dietary fiber supplementation on systemic inflammation and clinical parameters in patients with COPD through a randomized, double-blind, placebo-controlled trial.
Inclusion: Inclusion Criteria:; Diagnosis of COPD with no exacerbation episodes in the last 3 months; Aged 18 to 75 years; Patient at the Interstitial Lung Diseases Outpatient Clinic of Hospital das Clínicas da UFMG; Ability to perform spirometry; Ability to perform the 6-minute walk test (6MWT); Willingness to participate in the study and signed Informed Consent Form (ICF); Ability to read and write; Daily dietary fiber intake between 10 and 20 grams.
Exclusion: Lung transplant recipients; Diagnosed COPD exacerbation (ECOPD) within the 3 months prior to study start; Major changes in COPD maintenance therapy within 3 months prior to screening; Use of a short course of oral corticosteroids within 4 weeks prior to Day 1 of the study; Interstitial lung disease; Severe comorbidities impacting outcomes (severe pancreatic, hepatic, renal, or cardiac disease; inflammatory bowel disease; active neoplasm with prognostic impact; human immunodeficiency virus/AIDS; active pulmonary tuberculosis; multiple sclerosis); Any other condition identified during the screening visit by the investigator or nurse that could interfere with the study or patient safety; Recent acute respiratory infection; End-stage COPD (GOLD stage 4); Primary diagnosis of asthma; Unwillingness or inability to comply with study procedures (e.g., inability to record dietary intake, attend visits, or manage oral supplementation); Pregnant, breastfeeding, or planning to become pregnant; Change in smoking habits within the last 6 months; Requirement for other nutritional supplements or parenteral nutrition; Daily dietary fiber intake exceeding 28 grams for women or 34 grams for men.